<?xml version="1.0" encoding="UTF-8"?>
<p>In tyrosine kinase inhibitors (TKI)-treated chronic myeloid leukemia (CML), the proportion of 
 <italic>BCR-ABL1</italic> mRNA is used to monitor the individual treatment response.
 <sup>
  <xref rid="b1-1031825" ref-type="bibr">1</xref>–
  <xref rid="b3-1031825" ref-type="bibr">3</xref>
 </sup> Most patients show a typical bi-phasic response with a steep, initial decline (slope 
 <italic>α</italic>), followed by a slower, secondary decline (slope 
 <italic>β</italic>) of 
 <italic>BCR-ABL1</italic> levels.
 <sup>
  <xref rid="b4-1031825" ref-type="bibr">4</xref>–
  <xref rid="b6-1031825" ref-type="bibr">6</xref>
 </sup> Whereas the initial decline is attributed to the eradication of proliferating leukemic cells (LC), the secondary decline has been suggested to result from a slower eradication of quiescent leukemic stem cells (LSCs).
 <sup>
  <xref rid="b5-1031825" ref-type="bibr">5</xref>–
  <xref rid="b7-1031825" ref-type="bibr">7</xref>
 </sup> About two-thirds of the patients achieve major molecular remission (MMR), i.e. a reduction of three logs from the baseline (MR3), while one-third of these even achieve deep molecular remission (DMR, i.e. MR4.5) within five years of treatment.
 <sup>
  <xref rid="b3-1031825" ref-type="bibr">3</xref>,
  <xref rid="b6-1031825" ref-type="bibr">6</xref>,
  <xref rid="b8-1031825" ref-type="bibr">8</xref>
 </sup>
</p>
